@article{a81fa65eb0c4432188d964bbbcf90807,
title = "The European medical information framework: A novel ecosystem for sharing healthcare data across Europe",
abstract = "Introduction The European medical information framework (EMIF) was an Innovative Medicines Initiative project jointly supported by the European Union and the European Federation of Pharmaceutical Industries and Associations, that generated a common technology and governance framework to identify, assess and (re)use healthcare data, to facilitate real-world data research. The objectives of EMIF included providing a unified platform to support a wide range of studies within two verification programmes-Alzheimer's disease (EMIF-AD), and metabolic consequences of obesity (EMIF-MET). Methods The EMIF platform was built around two main data-types: electronic health record data and research cohort data, and the platform architecture composed of a set of tools designed to enable data discovery and characterisation. This included the EMIF catalogue, which allowed users to find relevant data sources, including the data-types collected. Data harmonisation via a common data model were central to the project especially for population data sources. EMIF also developed an ethical code of practice to ensure data protection, patient confidentiality and compliance with the European Data Protection Directive, and GDPR. Results Currently 18 population-based disease agnostic and 60 cohort-based Alzheimer's data partners from across 14 countries are contained within the catalogue, and this will continue to expand. The work conducted in EMIF-AD and EMIF-MET includes standardizing cohorts, summarising baseline characteristics of patients, developing diagnostic algorithms, epidemiological studies, identifying and validating novel biomarkers and selecting potential patient samples for pharmacological intervention. Conclusions EMIF was designed to provide a sustainable model as demonstrated by the sustainability plans for EMIF-AD. Although network-wide studies using EMIF were not conducted during this project to evaluate its sustainability, learning from EMIF will be used in the follow-on IMI-2 project, European Health Data and Evidence Network (EHDEN). Furthermore, EMIF has facilitated collaborations between partners and continues to promote a wider adoption of principles, technology and architecture through some of its continued work.",
keywords = "catalogue, EMIF, EMIF-AD, EMIF-MET, use case, MILD COGNITIVE IMPAIRMENT, FATTY LIVER-DISEASE, TRANSLATIONAL RESEARCH, CLINICAL-RESEARCH, PREVALENCE, DEMENTIA, BIOMARKERS, DATABASES, PLATFORM, SUPPORT",
author = "Simon Lovestone and Bart Vannieuwenhuyse and Pieter-Jelle Visser and Isabelle Bos and Stephanie Vos and Johannes Streffer and Ulf Smith and Dawn Waterworth and {van der Lei}, Johan and Peter Rijnbeek and Oliveira, {Jose Luis} and {Van Speybroeck}, Michel and Rudi Verbeeck and Dipak Kalra and Nathan Lea and Eva Molero and Martine Lewi and Myriam Alexander and Glen James and Caroline Sage and Jelle Praet and Peter Egger and Gurparkash Singh and Nigel Hughes and {EMIF Consortium}",
note = "Funding Information: The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement number 115372, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007‐2013) and EFPIA companies' in‐kind contribution. The writing of this manuscript was funded by Janssen Research & Development, LLC. Jerboa code development was performed by Mees Mosseveld and Marius Gheorghe at Erasmus MC in close collaboration with the Use Case teams. The OHDSI community supported the adoption of the OMOP‐CDM and their tools. The knowledge objects framework was conceived and implemented by Rudi Verbeeck, Michel van Speybroeck Alvaro Cortes‐Callabuig and Luiza Gabriel at Janssen and by James Cunningham (Manchester University). The knowledge object library was mainly built by Serge Eifes, Adriano Barbosa, Kavita Rege at Information Technology for Translational Medicine (ITTM). Significant contributions to the technical implementation were done by Bart Maertens at Know.Bi. Cohort onboarding and harmonization was performed by Isabelle Bos and Stephanie Vos at Maastricht University. Coordination with EMIF‐Platform was done by Rudi Verbeeck and Caroline Sage at Janssen. Upload to tranSMART, including server maintenance was done by Janneke Schoots‐van der Ploeg, Olaf Meuwese, Andy Sewgobind and Stefan Payralbe at the Hyve. Glen James was an employee at GSK at the time of this work. The names of the writers who contributed to the design, drafting, editing, reviewing and final approval of the manuscript are as below: Bart Vannieuwenhuyse (Janssen Pharmaceutica NV, Belgium) Simon Lovestone (University of Oxford, UK) Pieter‐Jelle Visser (Maastricht University, The Netherlands) Isabelle Bos (Maastricht University, The Netherlands) Stephanie Vos (Maastricht University, The Netherlands) Johannes Streffer (UCB, Belgium) Ulf Smith (University of Gothenburg, Sweden) Dawn Waterworth (GSK, US) Johan van der Lei (Erasmus Medical Center Rotterdam, The Netherlands) Peter Rijnbeek (Erasmus Medical Center Rotterdam, The Netherlands) Jose Luis Oliveira (University of Aveiro, Portugal) Van Speybroeck, Michel (Janssen Pharmaceutica NV, Belgium) Rudi Verbeeck (Janssen Pharmaceutica NV, Belgium) Dipak Kalra (iHD, Belgium) Nathan Lea (University college London, UK) Eva Molero (Synapse Research Management Partners, Spain) Martine Lewi (Janssen Pharmaceutica NV, Belgium) Myriam Alexander (Open Vie, UK) James, Glen (AstraZeneca, UK) Sage, Caroline (Modis, Belgium) Praet, Jelle (Modis, Belgium) Peter Egger (GSK, UK) Gurparkash Singh (Janssen Research & Development, US) Nigel Hughes (Janssen Pharmaceutica NV, Belgium) Funding Information: The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement number 115372, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies' in-kind contribution. The writing of this manuscript was funded by Janssen Research & Development, LLC. Jerboa code development was performed by Mees Mosseveld and Marius Gheorghe at Erasmus MC in close collaboration with the Use Case teams. The OHDSI community supported the adoption of the OMOP-CDM and their tools. The knowledge objects framework was conceived and implemented by Rudi Verbeeck, Michel van Speybroeck Alvaro Cortes-Callabuig and Luiza Gabriel at Janssen and by James Cunningham (Manchester University). The knowledge object library was mainly built by Serge Eifes, Adriano Barbosa, Kavita Rege at Information Technology for Translational Medicine (ITTM). Significant contributions to the technical implementation were done by Bart Maertens at Know.Bi. Cohort onboarding and harmonization was performed by Isabelle Bos and Stephanie Vos at Maastricht University. Coordination with EMIF-Platform was done by Rudi Verbeeck and Caroline Sage at Janssen. Upload to tranSMART, including server maintenance was done by Janneke Schoots-van der Ploeg, Olaf Meuwese, Andy Sewgobind and Stefan Payralbe at the Hyve. Glen James was an employee at GSK at the time of this work. The names of the writers who contributed to the design, drafting, editing, reviewing and final approval of the manuscript are as below: Bart Vannieuwenhuyse (Janssen Pharmaceutica NV, Belgium) Simon Lovestone (University of Oxford, UK) Pieter-Jelle Visser (Maastricht University, The Netherlands) Isabelle Bos (Maastricht University, The Netherlands) Stephanie Vos (Maastricht University, The Netherlands) Johannes Streffer (UCB, Belgium) Ulf Smith (University of Gothenburg, Sweden) Dawn Waterworth (GSK, US) Johan van der Lei (Erasmus Medical Center Rotterdam, The Netherlands) Peter Rijnbeek (Erasmus Medical Center Rotterdam, The Netherlands) Jose Luis Oliveira (University of Aveiro, Portugal) Van Speybroeck, Michel (Janssen Pharmaceutica NV, Belgium) Rudi Verbeeck (Janssen Pharmaceutica NV, Belgium) Dipak Kalra (iHD, Belgium) Nathan Lea (University college London, UK) Eva Molero (Synapse Research Management Partners, Spain) Martine Lewi (Janssen Pharmaceutica NV, Belgium) Myriam Alexander (Open Vie, UK) James, Glen (AstraZeneca, UK) Sage, Caroline (Modis, Belgium) Praet, Jelle (Modis, Belgium) Peter Egger (GSK, UK) Gurparkash Singh (Janssen Research & Development, US) Nigel Hughes (Janssen Pharmaceutica NV, Belgium) The names of the institutions, including academic and industry partners, part of EMIF Consortium are as below: Aarhus Universitetshospital Agenzia Regionale di Sanita Alzheimer Europe Amgen NV Boehringer Ingelheim International GmbH Cambridge Cognition LTD Concentris Research Management GmbH Custodix NV Electrophoretics Ltd Erasmus Universitair medisch centrum Rotterdam European Molecular Biology Laboratory F. Hoffman-La Roche AG Fondazione PENTA?For the treatment and care of children with HIV-ONLUS Fundaci? Institut Universitari per a la Recerca a l'Atenci? Prim?ria de Salut Jordi Gol i Gurina GENOMEDICS S.R.L. GlaxoSmithKline R&D LTD Goeteborgs Universitet Helsingin yliopisto Institut de recerches internationals SERVIER Institut National de Ia Sante et de Ia Recherche M?dicale It?-Suomen Yliopisto Janssen Pharmaceutica NV Karolinska Institutet King's College London Leibniz-Institut f?r Pr?ventionsforschung und Epidemiologie-BIPS GmbH Maastricht University MAAT France Merck KGaA Novo Nordisk A/S Pfizer Limited PHARMO Institute N.V. Provincia Lombardo-Veneta - Ordine Ospedaliero di San Giovanni di Dio? Fatebenefratelli Societa Servizi Telematici SRL Sorbonne Universit? Stichting Informatievoorziening voor Zorg en Onderzoek Stichting VUmc Synapse Research Management Partners S.L. Tartu Ulikool Teknologian tutkimuskeskus VTT Oy The Chancellor, Masters and Scholars of the University of Cambridge The Chancellor, Masters and Scholars of the University of Oxford The European Institute for Health Records The University of Exeter UCB Biopharma SPRL Universidade de Aveiro Universit? degli Studi di Pisa Universit?t Leipzig Universitat Pompeu Fabra Universit?tsklinikum Erlangen, Anstalt des ?ffentlichen Rechts Universit?tsklinikum Schleswig-Holstein Universit? Paul Sabatier Toulouse III Universiteit Antwerpen University College London University of Copenhagen University of Glasgow University of Leicester University of Luebeck University of Manchester Vestische Caritas-Kliniken GmbH VIB The authors would also like to acknowledge Avadhoot Avadhani, MDS, PhD (Tata Consultancy Services, India) for providing writing assistance, and Padmini Chitale, M Pharm (Tata Consultancy Services, India) for revising the manuscript in response to reviewer's comments. Publisher Copyright: {\textcopyright} 2019 The Authors. Learning Health Systems published by Wiley Periodicals, Inc. on behalf of the University of Michigan",
year = "2020",
month = apr,
doi = "10.1002/lrh2.10214",
language = "English",
volume = "4",
journal = "Learning health systems",
issn = "2379-6146",
publisher = "John Wiley & Sons Inc.",
number = "2",
}